NCT05326464View on ClinicalTrials.gov

Tofacitinib in Recurrent GBM Patients

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

Glioblastoma

Interventions

DRUG

Tofacitinib 10mg

10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER